Health, Brescianini (Amgen Italia): “The BiTE platform combines biology and technology in an unprecedented way”

“In developing the BiTE platform, Amgen had an extremely innovative approach, based on the unprecedented connection between biology and technology. We started from acute lymphoblastic leukemia in the refractory relapse phase and then advanced towards earlier phases of the disease, passing through the so-called minimal residual disease until reaching front-line development. All this was possible thanks to Amgen’s innovative approach, but also thanks to the fundamental and decisive contribution of the international hematology community and, in particular, the Italian one”. Thus Alessandra Brescianini, medical director of Amgen Italia, on the sidelines of the event with which Amgen illustrated the results of the Phase III E1910 clinical study, which demonstrate how the introduction of the bispecific antibody blinatumomab in the first line of treatment significantly increases the Overall survival of patients with newly diagnosed Ph- B lymphocyte acute lymphoblastic leukemia (ALL).